A Comparative Evaluation of the Efficacy of ‘OPG- assisted Inferior Alveolar Nerve Block’ Technique with the Conventional Technique in Permanent Mandibular Molars with Symptomatic Irreversible Pulpitis : A Randomized Double-blinded Clinical Study ?

Dr DIKSHIT SOLANKI0 个研究点目标入组 34 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1.Systemically healthy Patients (ASA 1 & 2) between age group of 18-60 years will be included in the study.
•2.Patients with pre-operative moderate to severe pain i.e. VAS score of 4 and above in mandibular molars will be included in the study.
•3.Patient having fully erupted last tooth in the mandibular arch upto the level of occlusion will be included in the study.
•4.Patients showing hyper response to cold and electric pulp testing (EPT) will be included in the study.
•5.Patients with symptomatic irreversible pulpitis with/without symptomatic apical periodontitis (only vital teeth) will be included in the study.
•6.Patients requiring treatment of multiple teeth along with the concerned tooth will be included in the study.
•7.A written informed consent will be taken from all the patients and only those patients ready to sign the consent form will be included in the study.

•1.Asymptomatic Non-Vital Teeth with/without periapical radiolucency be it abscess or granuloma etc will be excluded.
•2.Patients showing active sites of pathosis in the injection area.
•3.Medically compromised patients will be excluded.
•4.Teeth with completely obliterated canals will be excluded
•5.Teeth with open apex, root resorption or complex root canal anatomy will be excluded.
•6.Teeth with vertical root fractures, cracks, etc will be excluded.
•7.Patient with deep periodontal disease or endo-perio lesion with periodontal phase dominant will be excluded.
•8.Patients with restricted mouth opening will be excluded.
•9.Pregnant and lactating women will be excluded.
•10.Patients using medications that might affect the anesthetic assessment will be excluded.
•11.Patients allergic to lidocaine and/or adrenaline will be excluded.

发起方

Dr DIKSHIT SOLANKI